Organogenesis Holdings ORGO Estimates

NASDAQ ORGO
$1.59 -0.01 (-0.94%)
As of: Sep 9, 2026 · 11:21 AM EDT
Analyst Estimates

Organogenesis Holdings Inc. Revenue Estimates

Periods 22
Next Period Q3 26
Consensus 53.88 M

Analysts expect Organogenesis Holdings Inc. to report revenue of 53.88 M for Q3 26, against a range of 48.87 M to 58.88 M. The most recent reported quarter, Q2 26, came in at 43.76 M, a 15.4% miss against the 51.73 M consensus.

Metric Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27Q1 28Q2 28Q3 28Q4 28Q1 29Q2 29Q3 29Q4 29
Reported (Actual) 115.18 M126.66 M86.69 M101.00 M150.86 M225.07 M36.25 M43.76 M--------
High Estimate 107.69 M109.36 M92.14 M112.42 M135.61 M192.95 M49.36 M54.49 M58.88 M66.19 M61.60 M68.67 M72.00 M82.76 M57.25 M71.52 M
Low Estimate 98.29 M94.90 M82.53 M102.28 M124.56 M174.54 M43.20 M48.97 M48.87 M54.96 M52.47 M57.48 M65.22 M73.85 M49.97 M66.88 M
Consensus Estimate 102.99 M102.13 M87.33 M107.35 M130.08 M183.75 M46.28 M51.73 M53.88 M60.58 M57.04 M63.08 M68.61 M78.31 M53.61 M69.20 M
Analyst Estimates

Organogenesis Holdings Inc. Earnings Per Share (EPS) Estimates

Periods 22
Next Period Q3 26
Consensus -0.18

Analysts expect Organogenesis Holdings Inc. to report earnings per share of -0.18 for Q3 26, against a range of -0.19 to -0.17. The most recent reported quarter, Q2 26, came in at -0.71, a 97.2% miss against the -0.36 consensus.

Metric Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27Q1 28Q2 28Q3 28Q4 28Q1 29Q2 29Q3 29Q4 29
Reported (Actual) 0.090.04-0.17-0.060.120.31-0.37-0.71--------
High Estimate -0.02-0.01-0.04-0.050.070.24-0.28-0.35-0.17-0.14-0.07-0.060.090.06-0.17-0.14
Low Estimate -0.02-0.01-0.04-0.050.070.20-0.34-0.37-0.19-0.16-0.09-0.060.090.06-0.19-0.16
Consensus Estimate -0.02-0.01-0.04-0.050.070.22-0.31-0.36-0.18-0.15-0.08-0.060.090.06-0.18-0.15